PulmonologyNews.net

Pulmonology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Pneumonia"

Asthma is an independent risk factor for invasive pneumococcal disease. The risk among persons with asthma is at least double that among controls. Pneumococcal disease is caused by a common bacteri ...


Cyclophosphamide, a drug that suppresses the immune system and reduces inflammation, has been shown to be effective in treating lung disease associated with scleroderma, a connective tissue disease. . ...


A study demonstrated that patients with uncomplicated lower respiratory tract infections, such as bronchitis, who were given antibiotics had little difference in symptom relief compared to patients wh ...


A carefully implemented system of pneumonia care can lead to better outcomes and fewer unnecessary hospitalizations, according to a University of Pittsburgh School of Medicine study, published in the ...


A research has shown that idiopathic interstitial pneumonia ( IIP ), a group of potentially fatal disorders that affects the lungs, may be caused by an interaction between a specific genetic backgroun ...


Hospitalization rates for pneumonia have increased substantially for U.S. adults 65 to 84 years of age. Pneumonia is among the top 10 causes of death in the United States and is a significant caus ...


An antibiotic medication, Moxifloxacin ( Avelox ), proved more effective at knocking out community-acquired pneumonia ( CAP ) in patients 65 and older than the antibiotic that has been the front-line ...


A study found that taking antibiotics for three days is just as effective for community acquired pneumonia as continuing treatment for the recommended 7-10 days. Shorter treatment can also help conta ...


The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Relvar Ellipta ( Fluticason ...


Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting beta-2 agonist is more protective than a once-daily longacting beta-2 agonist alone against exacerbations of ...


In clinical trials, the use of inhaled corticosteroids is associated with an increased risk of pneumonia in people with COPD, but whether the same is true for people with asthma is not known.With the ...


Inhaled corticosteroids are known to increase the risk of pneumonia in patients with chronic obstructive pulmonary disease ( COPD ). It is unclear whether the risk of pneumonia varies for different in ...


Respiratory pathogens are frequently isolated from the airways in patients with chronic obstructive pulmonary disease ( COPD ) in the absence of an exacerbation. This bacterial colonization by potenti ...


Pfizer has presented detailed results of the CAPiTA ( Community-Acquired Pneumonia Immunization Trial in Adults ), the landmark study of approximately 85,000 subjects, demonstrating that Prevenar 13 ( ...


There is controversy regarding the impact of chronic obstructive pulmonary disease ( COPD ) in clinical outcomes in elderly patients with pneumonia. Comorbidities such as cardiovascular disease have ...